IGC Pharma Sells Non-Core Facility for $2.7 Million
IGC Pharma Inc. has sold a non-core manufacturing facility for $2.7 million, resulting in a non-cash profit of $1.1 million and reducing annual operating expenses by $600,000. The deal also provides long-term preferential supply rights, enhancing financial flexibility. This strategic divestiture was announced on November 17, 2025, and aims to improve the company's financial position.
IGC Pharma Inc. has executed a strategic divestiture of a non-core manufacturing facility valued at $2.7 million as of September 29, 2025. The transaction resulted in a non-cash profit of approximately $1.1 million and eliminated $600,000 in annual operating expenses. The deal also secures long-term preferential supply rights of future sale proceeds, enhancing the company’s financial flexibility. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102935) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
